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Abstract
Introduction: Aberrant activation of Wnt/b-catenin signaling plays an important role in the pathogenesis of breast
cancer. DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/b-catenin signaling through
interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in breast tumorigenesis
remains unclear.
Methods: We examined DACT1 expression in breast cancer cell lines and primary tumors with semiquantitative or
quantitative RT-PCR and immunochemistry, and further evaluated the promoter methylation of DACT1 with
methylation-specific PCR (MSP). We also explored the tumor-suppressive functions of DACT1 in vivo and in vitro,
and its related mechanism in breast cancer.
Results: We identified DACT1 as a methylated target in our breast cancer epigenome study. Here, we further
investigated DACT1 expression in multiple breast cell lines and primary tumors, and further studied its function and
molecular mechanisms. We found that DACT1 expression was silenced in eight (88.9%) of nine breast cancer cell
lines, and its protein levels were obviously reduced in breast tumors compared with paired surgical-margin tissues.
Promoter CpG methylation of DACT1 was detected in five (55.6%) of nine breast cancer cell lines and 40 (29.9%) of
134 primary tumors, but not in surgical-margin tissues and normal breast tissues. Demethylation treatment of
breast cancer cell lines restored DACT1 expression along with promoter demethylation, suggesting that an
epigenetic mechanism mediates DACT1 silencing in breast cancer. Functional assays showed that ectopic
expression of DACT1 could inhibit breast tumor cell proliferation in vivo and in vitro through inducing apoptosis,
and further suppress tumor cell migration through antagonizing the Wnt/b-catenin signaling pathway.
Conclusions: Our study demonstrates that DACT1 could function as a tumor suppressor but was frequently
downregulated in breast cancer.
Introduction
Breast cancer is the leading cause of cancer death
among females [1], and results from accumulated
genetic and epigenetic alterations of various cancer
genes, including tumor-suppressor genes (TSGs) and
oncogenes [2]. Epigenetic alterations, especially CpG
promoter methylation, play important roles in the initia-
tion and progression of multiple cancers including
breast cancer. Hypermethylation of CpG island (CGI) in
the promoter regions of TSGs is an alternative mechan-
ism for TSG silencing and could occur early in tumori-
genesis, thus serving as a promising tumor marker for
breast cancer diagnosis [3]. Aberrant promoter methyla-
tion of some TSGs, such as RASSF1A, BRCA1, TWIST,
Cyclin D2, and p16, has been shown to be good biomar-
kers for the early detection or for a therapeutic target in
breast cancer [4,5].
Wnt/b-catenin signaling plays an important role in mul-
tiple tumorigenesis, including breast cancer [6]. Epigenetic
silencing of negative regulators of WNT signaling is
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crucial for the aberrant activation of WNT/b-catenin
signaling in tumor pathogenesis [5,7]. DACT1, a homolo-
gue of Dapper, located at chromosomal region 14q23.1,
was first identified as a Dishevelled (Dvl)-associated
antagonist of Wnt/b-catenin and JNK signaling pathways
[8,9], DACT1 is expressed during embryonic development
in the adult brains of mice [10,11], but studies on its role
in tumorigenesis are scanty. DACT1 has been shown to be
reduced in several tumors, such as gastrointestinal stromal
tumors [12] and non-small cell lung cancer (NSCLC) [13],
but overexpressed in some other tumors [14,15]. Dysregu-
lated DACT1 was associated with poor prognosis in
tumor patients [13]. DACT1 was also reported to be a
novel inhibitor of the WNT/b-catenin signaling in hepato-
cellular carcinoma (HCC) [16]. However, its expression
and biologic functions in breast cancer pathogenesis are
unknown.
We identified DACT1 as a methylated target in the
MB231 breast cancer cell line as compared with normal
tissue in our pilot cancer epigenome study. Here, we
further examined the expression and promoter methyla-
tion of DACT1 in multiple breast cell lines and primary
tumors, and evaluated its potential as a tumor biomarker
for breast cancer. We further demonstrated the biologic
functions of DACT1 in breast cancer cells in vivo and in
vitro in the context of the Wnt/b-catenin signaling
pathway.
Materials and methods
Cell lines, tumor samples, and normal tissues
Several breast cancer cell lines (BT549, MDA-MB-231,
MDA-MB-468, MCF-7, T47D, SK-BR-3, YYC-B1, YCC-
B3, and ZR-75-1) were studied. All cell lines were main-
tained at 37°C in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS; Invitrogen, Carlsbad, CA, USA),
100 U/ml of penicillin, and streptomycin.
Normal human breast tissue RNA samples were pur-
chased commercially (Stratagene, La Jolla, CA, USA;
Millipore Chemicon, Billerica, MA, USA; BioChain Insti-
tute, Hayward, CA, USA). Primary breast tumor sam-
ples, paired surgical-margin tissues, and normal breast
tissues were obtained from the First Affiliated Hospital
of Chongqing Medical University, or elsewhere, as
described previously [17-19]. All samples were evaluated
and subject to histologic diagnosis by pathologists. Clini-
cal information, including age, tumor grade, tumor size,
follow-up data after initial diagnosis, and treatment, was
obtained for the majority of tumor cases. Grading of
tumors was achieved by staining with hematoxylin and
eosin (H&E). All patients provided written consent for
the study. The study was approved by the Ethics Com-
mittee of the First Affiliated Hospital of Chongqing
Medical University (Approval notice: 2010/2012(23)).
Semiquantitative RT-PCR analysis
Total RNA was isolated from cell lines by using TRI
Reagent (Molecular Research Center, Cincinnati, OH,
USA). Semiquantitative RT-PCR was performed as
described previously [20]. GAPDH was amplified as a
control. Primer sequences are listed in Table 1. RT-PCR
was performed with 32 cycles for DACT1, and 23 cycles
for GAPDH, by using Go-Taq (Promega, Madison, WI,
USA).
5-Aza-2’-deoxycytidine and trichostatin A treatment
Cell lines were treated with 10 mM 5-aza-2’-deoxycyti-
dine (Aza; Sigma-Aldrich, St Louis, MO, USA) for 3
days or further treated with 100 nM trichostatin A
(TSA; Cayman Chemical Co., Ann Arbor, MI, USA) for
14 hours.
DNA bisulfite treatment and methylation-specific PCR
Genomic DNA was extracted from tumors, normal tissues,
and cell pellets by using QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany). Bisulfite modification of DNA and
methylation-specific PCR (MSP) were performed as
described previously [21,22]. Bisulfite-treated DNA was
amplified by MSP with DACT1 methylation-specific
primer set for DACT1 promoter (Table 1), by using
AmpliTaq-Gold DNA Polymerase (Applied Biosystems,
Foster City, CA, USA). Methylated and unmethylated
MSP primer sets target the same CpG sites and do not
amplify genomic DNA with no bisulfite treatment.
Quantitative reverse transcription polymerase chain
reaction
Real-time PCR (rtPCR) was performed by using Maxima
SYBR Green/ROX qPCR Master Mix (MBI Fermentas,
St. Leon-Rot, Germany) (Table 1). Thermal-cycling reac-
tion was performed in the 7500 Real-Time PCR System
(Applied Biosystems). Melting-curve analysis and agar-
ose gel electrophoresis of PCR products were further
performed. Relative expression levels of DACT1 in
breast tissues were standardized to b-actin levels.
Tissue microarray and immunohistochemistry
To evaluate DACT1 expression in breast tissues, tissue
microarray (TMA) was used as described previously, con-
taining 30 pairs primary tumors and corresponding
tumor-margin tissues [18]. Immunohistochemistry was
performed by using a two-step method. In brief, after
deparaffinization, sections were hydrated and underwent
sodium citrate antigen retrieval. Sections were then incu-
bated with 3% hydrogen peroxide to block endogenous
peroxidase activity. A rabbit polyclonal antibody against
human DACT1 protein (Ab104.4; Abcam, Cambridge,
UK) was used. Sections were incubated with primary
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antibody (1:200 dilution) overnight at 4°C, detected by
using polyperoxidase-anti-rabbit IgG (Jackson Immunor-
esearch Laboratories, West Grove, PA, USA), and coun-
terstained with hematoxylin. To eliminate nonspecific
staining, a negative control was performed with PBS.
All immunohistochemical photographs were analyzed by
using Image Pro Plus (IPP, version 6.0; Media Cybernetics,
Silver Spring, MD, USA), as described previously [18]. The
mean optical density (OD), as a quantitative measure of
stain intensity, was analyzed to determine average protein
expression.
Immunofluorescence staining
Cells transfected with pcDNA3.1-DACT1 or pcDNA3.1
plasmid were grown on glass coverslips. Transfected cells
were washed with PBS, fixed with 4% paraformaldehyde in
PBS for 15 minutes, permeabilized with 0.5% Triton X-100
for 30 minutes, and blocked with 3% bovine serum albumin
in PBS at 37°C for 60 minutes. Cells were incubated with
primary antibodies diluted in TBST at 4°C for 12 hours,
washed twice with PBS, and then incubated with DyLight-
conjugated anti-rabbit or anti-mouse antibody (CoWin Bio-
tech Co., Ltd. (CWBIO), Beijing, China) for an additional
50 minutes. Nuclei were counterstained with 4,6-diami-
dino-2-phenylindole (DAPI) (Roche, Palo Alto, CA, USA).
Cell-proliferation assay
MB231 cells were cultured in six-well plates at a density
of 1 × 104 cells/well and allowed to grow overnight.
Cultures were then transfected with pcDNA3.1-DACT1
or pcDNA3.1 plasmid by using Lipofectamine-2000 (Invi-
trogen). At 24, 48, and 72 hours, cell proliferation was
measured by using Cell Counting Kit-8 (CCK-8; Dojindo
Molecular Technologies, Inc., Kumamoto, Japan) [23].
Colony-formation assay
Colony-formation assay was performed by using a mono-
layer culture. Cells (MB231 and MCF7) were plated in
six-well plates and transfected with pcDNA3.1-DACT1
or pcDNA3.1 (4 μg each) plasmid by using Lipofectamine
2000 (Invitrogen). At 48 hours after transfection, cells
were collected, replated, and selected for 2 weeks in the
presence of G418 (0.4 mg/ml). Surviving colonies (≥50
cells/colony) were counted after staining with gentian
violet. All experiments were performed 3 times.
Wound-healing assay
DACT1 and vector-expressing cells (MB231 and MCF7)
were selected by using G418, and then cultured in six-
well plates until confluent. After scratching the mono-
layer, cells were photographed at 0, 12, 24, 36, 42, and
48 hours under a 10× objective (Leica DMI4000B, Milton
Keynes, Bucks, UK).
Caspase-3 colorimetric assay
Cells were seeded in six-well plates and transfected with
pcDNA3.1-DACT1 or pcDNA3.1 plasmid, and then col-
lected and lysed for protein purification at 24 or 48 hours.
Total protein extraction was performed for analyzing
active caspase-3 by using Caspase-3 Colorimetric Assay
Kits (KeyGen Biotech Co, Nanjing, China).
Western blot
Transfected cells were lysed in M-PER Mammalian Pro-
tein Extraction Reagent (Pierce, Thermo Scientific,
Cramlington, UK) containing a protease inhibitor cock-
tail (Sigma Aldrich). A total of 50 μg of protein lysate
for each sample was separated by using sodium dodecyl-
sulfate/polyacrylamide gel electrophoresis (SDS-PAGE).
The lysates were then transferred to PVDF membranes
for antibody incubation. After blocking with 5% nonfat
milk and 0.1% Tween 20 in TBS, the membranes were
incubated with DACT1 antibody (Abcam, Cambridge,
UK), or antibodies to active b-catenin (Millipore, Biller-
ica, MA, USA), cyclin D1, c-Myc, cleaved caspase 3, and
cleaved PARP (Epitomics Inc., Burlingame, CA, USA).
Table 1 List of primers used in this study
PCR Primer Sequence (5’-3’) Product size (bp) PCR cycles Annealing temperature (°C)
MSP DACT1m3 CGGGATAGTAGTAGTCGGC 118 41 60
DACT1m4 CGCTAAAACTACGACCGCG
DACT1u3 GTTGGGATAGTAGTAGTTGGT 123 41 58
DACT1u4 AAACACTAAAACTACAACCACA
RT-PCR DACT1-F AGGAGAAGTTCTTGGAGGAG 179 32 55
DACT1-R TGAGCTAGGCCGACTGTCTG
GAPDH-F GGAGTCAACGGATTTGGT 206 23 55
GAPDH-R GTGATGGGATTTCCATTGAT
Real-time PCR DACT1-F GACGAGCAGAGCAATTACACC 158 40 60
DACT1-R ACCGTTTGAATGGGCAGA
b-actin-F CCTGTGGCATCCACGAAACT 314 40 60
b-actin-R GAAGCATTTGCGGTGGACGAT
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The immunoblots were visualized by using an enhanced
chemiluminescence detection system. GAPDH was used
as a control.
In vivo tumor model
Stable DACT1-expressing MB231 cells or controls (1 ×
106 cells in 0.2 ml PBS) were subcutaneously injected into
the right dorsal flank of female nude mice (6 weeks old,
six mice per group). The weight of nude mice was mea-
sured every 7 days for 4 weeks. The xenograft tumor
weight was assessed at the terminal time. The protocols
for in vivo animal experiment were approved by the Com-
mittee on Ethical Use of Animals of the First Affiliated
Hospital of Chongqing Medical University.
Statistical analysis
Statistical analyses were performed with SPSS version 16
(SPSS Inc., Chicago, IL, USA). Student t test was used to
analyze the difference of DACT1 expression between
breast cancer tissues and surgical margin tissues. c2 test
and Fisher Exact test were used to assess the correlation
between DACT1 methylation and clinicopathologic para-
meters. For all the tests, P < 0.05 was considered statisti-
cally significant.
Results
DACT1 is frequently reduced in breast cancer
We first examined DACT1 expression in a panel of
human normal adult tissues and fetal tissues, as well as
breast cancer cell lines, by using semiquantitative RT-
PCR. Results showed that DACT1 was widely expressed
in human normal tissues and fetal tissues, including nor-
mal breast tissues (Figure 1A, C), but was frequently
silenced or downregulated in breast cancer cell lines stu-
died (Figure 1C).
DACT1 expression in primary breast tumors was
further examined at the RNA and protein levels. We
found that DACT1 mRNA was obviously downregulated
in breast cancer tissues, compared with normal breast
tissues (*P < 0.01), as measured with qPCR (Figure 2A).
IHC was then performed to examine DACT1 expression
in 30 cases of primary tumors and paired surgical-margin
tissues (Figure 2B). An IPP system showed that the mean
optical density of DACT1 protein expression was signifi-
cantly decreased in primary breast tumors (0.222 ±
0.060), compared with that in surgical-margin tissues
(0.287 ± 0.054) (***P < 0.001) (Figure 2C).
We further assessed DACT1 expression by using the
Gene expression-based Outcome for Breast Cancer Online
(GOBO) database [24]. Gene-Set Analysis (GSA)-Tumor
showed that DACT1 is differently expressed among differ-
ent subtypes of breast cancer, with relatively high expres-
sion in a normal-like subtype (P < 0.00001; Figure 2D).
Furthermore, decreased expression of DACT1 was
associated with ER- and higher histologic grade (P <
0.00001, Figure 2E). These results indicate that DACT1
expression is frequently downregulated in breast cancer
and associated with clinicopathologic features.
Promoter methylation of DACT1 contributes to its
downregulation in breast cancer
We next evaluated whether DACT1 repression was due to
promoter methylation. A typical CpG island spanning the
proximal promoter and exon 1 regions of the DACT1
gene was found (Figure 1B). MSP showed that DACT1
was methylated in five breast cancer cell lines (MB231,
MB468, MCF7, T47D, and YCC-B1), although no methy-
lation was found in another two cell lines (SK-BR-3 and
ZR-75-1) with silenced DACT1 (Figure 1C). Pharmacolo-
gic demethylation was used to assess whether promoter
methylation directly regulates DACT1 expression. Three
cell lines (MB231, MCF7, and T47D) with methylated and
silenced DACT1 were treated with Aza and/or histone
deacetylase inhibitor TSA. After treatment, DACT1
expression was increased, accompanied by decreased
methylated alleles of DACT1 (Figure 1D). The results indi-
cate that promoter methylation is a major mechanism for
DACT1 silencing in breast cancer cells.
DACT1 is methylated in breast primary tumors
We further investigated DACT1 methylation in primary
tumors, surgical-margin tissues, and normal breast tissues.
DACT1 methylation was detected in 40 (29.9%) of 134
breast cancer tissues, but not in surgical-margin tissues
and normal breast tissues (Figure 3, Table 2), suggesting a
tumor-specific methylation of DACT1 in breast cancer.
We next analyzed the correlation between DACT1 methy-
lation and clinicopathologic features of breast cancer
patients, including age, tumor size, tumor grade, lymph
node metastasis, status of estrogen receptor (ER), proges-
togen receptor (PR), and HER2. However, no significant
correlation between DACT1 methylation and clinico-
pathologic features was found (Table 3).
Ectopic expression of DACT1 inhibits breast cancer cell
growth
DACT1 repression by promoter methylation in breast can-
cer indicated that DACT1 is likely a tumor suppressor.
Immunostaining showed that DACT1 is located mainly in
the cytoplasm and membrane of DACT1-expressing
MB231 cells (Figure 4A). Colony-formation assay and
CCK-8 cell-proliferation assay were further performed to
assess the effect of DACT1 on cell proliferation of breast
cancer. About 40% to 60% reduction of colony numbers
was observed in DACT1-transfected MB231 and MCF7
cells, compared with controls (*P < 0.05) (Figure 4B). Cell
viability was significantly decreased at 24, 48, and 72 hours
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after transfection with DACT1 in MB231 cells (**P < 0.01;
*P < 0.05) (Figure 4C).
To evaluate the molecular mechanism of DACT1 in the
inhibition of cell proliferation, caspase-3 colorimetric
assay was used. Results indicated that the concentration
of active caspase-3 was increased in DACT1-expressing
MB231 and MCF7 cells, compared with controls (**P <
0.01) (Figure 4D), as further confirmed by upregulated
cleaved caspase-3 and cleaved PARP (Figure 5C). Thus,
DACT1 is a functional TSG, inhibiting tumor cell growth
and inducing cell apoptosis of breast cancer.
DACT1 decreases b-catenin activity and suppresses breast
cancer cell migration
We next investigated whether DACT1 could counteract
Wnt/b-catenin signaling for its tumor-suppressive func-
tion. Expression and localization of active b-catenin were
examined with immunostaining and Western blot.
Reduced expression of active b-catenin and its down-
stream target gene c-MYC were detected in DACT1-
expressing MB231 cells (Figure 5), suggesting that
DACT1 antagonizes Wnt/b-catenin signaling by decreas-
ing active b-catenin levels in breast cancer.
As the Wnt/b-catenin signaling pathway plays a key role
in tumor metastasis, the effect of DACT1 on cell migration
was further analyzed. Wound-healing assay showed that
MB231 and MCF7 cells migrated into scraped areas within
42 and 48 hours, whereas DACT1 expression decreased
their wound closure by about 55% after 42 hours and
about 70% after 48 hours in these two cell lines (Figure 6),
suggesting that DACT1 attenuates the wound-induced cell
migration of breast cancer.
DACT1 inhibits breast tumor growth in vivo
Further to evaluate the tumor-suppressive functions of
DACT1 in vivo, tumorigenicity of MB231 cells expressing
Figure 1 Expression and promoter methylation of DACT1 in breast cancer. (A) DACT1 expression in human normal adult and fetal tissues
as detected by semiquantitative RT-PCR, with GAPDH as a control. (B) Schematic structure of the DACT1 promoter CpG island (CGI). Exon 1 (gray
rectangle), CpG sites (short vertical lines), transcription start site (curved arrow), and MSP sites analyzed are indicated. (C) DACT1 was silenced by
promoter methylation in breast cancer cell lines, but readily expressed in normal breast tissues. (D) Pharmacologic demethylation with Aza
combined with TSA (A+T) restored DACT1 expression in breast cancer cell lines. M, methylated; U, unmethylated.
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Figure 2 DACT1 was downregulated in primary breast tumors. (A) Analysis of DACT1 expression in normal breast tissues and primary breast
tumors by using real-time PCR. (B) Representative immunohistochemical (IHC) staining for DACT1 in paired breast tumors and surgical-margin
tissues. Magnification, 400×. (C) The mean optical density of DACT1 expression in each case (left panel). Quantitative analysis of DACT1
expression density is shown as values of mean ± SD (right panel). ***P < 0.001. (D, E) GSA-tumor analysis of DACT1 by using the 1,881-sample
breast cancer data set. Box plot of DACT1 expression for tumor samples stratified according to Hu subtypes, ER status, and histologic grade.
Yin et al. Breast Cancer Research 2013, 15:R23
http://breast-cancer-research.com/content/15/2/R23
Page 6 of 12
Figure 3 Representative methylation-specific PCR (MSP) analysis of DACT1 methylation in primary breast tumors, surgical margin
tissues, and normal tissues. M, methylated; U, unmethylated.
Table 2 Promoter methylation status of DACT1 in primary breast tumors
Tissue Samples (number) DACT1 promoter Frequency of methylation
Methylated Unmethylated
Breast cancer tissues 134 40 94 40/134 (29.9%)
Breast cancer surgical-margin tissues 11 0 11 0/11 (0%)
Normal breast tissues 15 0 15 0/15 (0%)
Table 3 DACT1 methylation and clinicopathologic features of breast tumors
Clinicopathologic features Number (N = 134) DACT1 methylation status P value
Methylated Unmethylated
Age (years) ≤40 11 2 9 0.229
> 40 86 30 56
Unknown 37 8 29
Tumor grade I 7 2 5 0.425
II 56 21 35
III 5 1 4
Unknown 66 16 50
Tumor size ≤2.0 cm 44 14 30 0.21
≥2.0 cm, ≤5.0 cm 48 18 30
> 5.0 cm 4 0 4
unknown 38 8 30
Lymph node metastasis Positive 43 16 27 0.38
Negative 41 12 29
Unknown 50 12 38
Distant metastasis Positive 1 1 0 0.114
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Table 3 DACT1 methylation and clinicopathologic features of breast tumors (Continued)
Negative 98 32 66
Unknown 35 7 28
ER status Positive 45 17 28 0.274
Negative 29 9 20
Unknown 60 14 46
PR status Positive 34 11 23 0.296
Negative 40 15 25
Unknown 60 14 46
HER2 status Positive 42 15 27 0.148
Negative 28 11 17
Unknown 64 14 50
ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; PR, progesterone receptor.
Figure 4 Tumor-suppressive functions of DACT1 in breast cancer cells. (A) Subcellular localization of DACT1 in MB231 cells was detected
with immunofluorescence. (B) Representative colony-formation assay of DACT1 in MB231 and MCF7 (left panel). Quantitative analyses of colony
numbers are shown as values of mean ± SD. *P < 0.05 (right panel, upper). DACT1 expression as measured with RT-PCR in vector- and DACT1-
transfected MB231 and MCF7 cells (right panel, lower). (C) Cell Counting Kit-8 (CCK8) assay assessed the effect of DACT1 on cell proliferation in
vector-, and DACT1- expressing MB231 cells. The values are shown as the mean ± SD. *P < 0.05; **P < 0.01. (D) The colorimetric assay for active
caspase-3 was performed in vector-, and DACT1-expressing MB231 and MCF7 breast cancer cells at 24 and 48 hours.
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DACT1 was evaluated in nude mice. Thirty days after
injection, tumors were excised from tested mice for
further analysis. The average volume of tumors induced
by DACT1-expressing MB231 cells was significantly
decreased, compared with control tumors (**P < 0.01;
Figure 7A, B). Immunohistochemistry was further
performed to analyze the expression of DACT1 and cell-
proliferation marker Ki-67 in xenograft tumors. Numer-
ous tumor cells with higher nuclear fragmentation were
observed in H&E-stained sections from DACT1-expres-
sing MB231 cells compared with controls, along with
decreased proliferating cells (Figure 7C). These results
indicate that DACT1 does act as a tumor suppressor in
breast tumorigenesis.
Discussion
From this study, we report that DACT1 is widely
expressed in normal breast tissues but frequently
downregulated/silenced by promoter methylation in
breast cancer. DACT1 is methylated in 29.9% of primary
breast tumors, but not in surgical-margin tissues and
normal breast tissues. DACT1 inhibits breast cancer cell
proliferation by inducing apoptosis, and further sup-
presses tumor-cell migration through downregulating b-
catenin activity, thus functioning as a tumor suppressor
for breast cancer.
Epigenetic disruption of TSGs, including promoter
methylation and histone modification, is a key mechanism
regulating cancer gene expression [25,26]. DACT1 was fre-
quently downregulated by promoter methylation in HCC,
whereas another DACT family member, DACT3, was
repressed by bivalent histone modifications in colon can-
cer [16,27]. We report that DACT1 was frequently methy-
lated in breast cancer cell lines and primary tumors, which
was correlated with its downregulation/silencing. No
methylation was detected in some breast cell lines with
Figure 5 DACT1 suppressed b-catenin activity and upregulated apoptotic markers. (A, B) Subcellular location of active b-catenin in vector-
and DACT1-expressing MB231 cells by immunostaining. (C) Western blot analysis of b-catenin signaling components and apoptotic markers.
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silenced DACT1, suggesting that histone modifications or
other mechanisms may be alternative mechanisms for
DACT1 downregulation in some settings.
The Wnt/b-catenin signaling pathway plays an impor-
tant role in tumor proliferation and migration [6]. Dact1
(Dapper), originally identified as an interacting protein
for Dishevelled (Dvl), has been involved in distinct
Wnt-dependent developmental processes of Xenopus,
zebrafish, and mice [8,11,28-30]. Dact1 antagonizes Wnt
signaling by binding with Dvl and promoting its degrada-
tion. Notably, this inhibitory activity is conserved from
Xenopus to humans [8,9,31,32]. DACT1 has been identi-
fied disrupting the expression and localization of
b-catenin, thus dysregulating Wnt/b-catenin signaling in
NSCLC [13]. We found that DACT1, located mainly in
the cytoplasm and membrane, reduced the expression of
active b-catenin and its downstream target gene c-MYC
in breast cancer cells, thus inhibiting cell proliferation of
breast cancer by inducing apoptosis, as well as tumor cell
migration.
DACT1 has been reported as a potential tumor marker
associated with poor prognosis of NSCLC [13]. We
observed tumor-specific methylation of DACT1 in breast
cancer, indicating its potential as a tumor marker, although
no obvious correlation between its methylation and clinico-
pathologic features was found, which must be further
Figure 6 Wound-healing assay for cell motility of vector- or DACT1-transfected MB231 and MCF7 cells. Upper: Representative images of
wound sealing at 0 hours and 42 or 48 hours after wound scratch. Lower: The percentage of wound sealing compared with that of controls at
each time point as indicated.
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confirmed by a large sample-sized study. Future study of
circulating methylated DACT1 in serum or in combination
with other methylated TSGs may be performed for the
detection of breast cancer [5,33,34].
Conclusions
In summary, DACT1, as a Wnt/b-catenin signaling
antagonist, is frequently downregulated/silenced in
breast cancer, acting as a functional tumor suppressor
in breast tumorigenesis, and may serve as a potential
tumor marker for breast cancer.
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